Insider-Favored Growth Stocks To Watch In October 2026
The United States market has remained flat over the last week but has experienced a 14% rise over the past year, with earnings forecasted to grow by 17% annually. In this context, growth companies with high insider ownership may present intriguing opportunities as they often reflect strong confidence from those closest to the business.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Upstart Holdings (UPST) | 14.0% | 69.5% |
| Standard Nuclear (STDN) | 18.8% | 64.2% |
| Sable Offshore (SOC) | 11.4% | 76% |
| Precigen (PGEN) | 11.7% | 54% |
| Nu Holdings (NU) | 22.8% | 22.3% |
| Himax Technologies (HIMX) | 29.1% | 70.2% |
| Figure Technology Solutions (FIGR) | 21.4% | 32.4% |
| Energy Vault Holdings (NRGV) | 10.5% | 67.3% |
| Dave (DAVE) | 16.6% | 24.1% |
| Almonty Industries (ALM) | 10.8% | 57.2% |
Let's uncover some gems from our specialized screener.
CarGurus (CARG)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: CarGurus, Inc. operates an online automotive platform facilitating the buying and selling of vehicles both in the United States and internationally, with a market cap of approximately $2.53 billion.
Operations: The company's revenue primarily comes from its Online Marketplaces segment, which generated $967.27 million.
Insider Ownership: 15%
CarGurus is experiencing strong earnings growth, forecasted at 21.23% annually, outpacing the US market's average. The company recently launched VINMax, enhancing its dealer platform with AI-driven marketing solutions that improve vehicle sales efficiency. Despite trading significantly below fair value estimates and having a high forecasted return on equity of 57.4%, CarGurus faces challenges such as reduced profit margins and no substantial insider buying in recent months.
- Click to explore a detailed breakdown of our findings in CarGurus' earnings growth report.
- The valuation report we've compiled suggests that CarGurus' current price could be quite moderate.
ImmunityBio (IBRX)
Simply Wall St Growth Rating: ★★★★★☆
Overview: ImmunityBio, Inc. is a biotechnology company that innovates and develops next-generation immunotherapies to enhance the immune system's response against cancer and infectious diseases, with a market cap of $10.73 billion.
Operations: The company generates revenue of $165.79 million from its focus on creating and advancing next-generation immunotherapies aimed at activating the immune system for long-lasting protection against cancer and infectious diseases.
Insider Ownership: 27.9%
ImmunityBio is forecast to achieve significant revenue growth of 49.5% annually, surpassing the US market average. Despite negative equity and substantial net losses, its valuation is considered attractive as it trades at 78.7% below fair value estimates. Recent strategic appointments, such as Dr. Jim Yong Kim as Vice Chairman, aim to bolster global partnerships and access to its immunotherapy platform following recent marketing authorizations for ANKTIVA in multiple countries including the UAE.
- Take a closer look at ImmunityBio's potential here in our earnings growth report.
- Insights from our recent valuation report point to the potential undervaluation of ImmunityBio shares in the market.
Hinge Health (HNGE)
Simply Wall St Growth Rating: ★★★★★★
Overview: Hinge Health, Inc. is a company dedicated to developing a scalable and automated health system through technology, with a market cap of $8.46 billion.
Operations: The company's revenue primarily comes from its Healthcare Software segment, generating $720.06 million.
Insider Ownership: 14.8%
Hinge Health demonstrates robust growth potential, with earnings projected to rise 27.7% annually, outpacing the US market average. Recent quarterly results show a shift to profitability with net income of US$43.69 million and a raised full-year revenue guidance between US$856 million and US$860 million. Insider activity has been modest, but strategic share buybacks totaling 13.88% indicate confidence in its valuation, which is significantly below fair value estimates.
- Click here to discover the nuances of Hinge Health with our detailed analytical future growth report.
- According our valuation report, there's an indication that Hinge Health's share price might be on the expensive side.
Make It Happen
- Discover the full array of 189 Fast Growing US Companies With High Insider Ownership right here.
- Contemplating Other Strategies? These 25 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com